Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) PT at $8.14

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $8.1429.

A number of brokerages recently issued reports on SANA. Citizens Jmp lifted their target price on Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research report on Thursday, October 30th. Bank of America boosted their price objective on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Wall Street Zen upgraded shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Wedbush lifted their price target on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Finally, HC Wainwright cut their price target on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, November 7th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SANA. Baillie Gifford & Co. boosted its holdings in shares of Sana Biotechnology by 13.6% in the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after buying an additional 1,371,775 shares during the last quarter. Vanguard Group Inc. raised its position in Sana Biotechnology by 19.9% during the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after acquiring an additional 1,517,474 shares in the last quarter. Marex Group plc acquired a new stake in Sana Biotechnology in the second quarter valued at $10,423,000. JPMorgan Chase & Co. grew its position in shares of Sana Biotechnology by 180.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after acquiring an additional 1,375,029 shares during the period. Finally, Integral Health Asset Management LLC increased its stake in shares of Sana Biotechnology by 33.3% during the 3rd quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock worth $7,100,000 after purchasing an additional 500,000 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Stock Up 0.9%

Shares of SANA stock opened at $4.56 on Thursday. The firm has a fifty day moving average of $4.27 and a 200-day moving average of $4.02. Sana Biotechnology has a 12-month low of $1.26 and a 12-month high of $6.55. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -4.70 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.03. On average, equities analysts expect that Sana Biotechnology will post -1.16 EPS for the current year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.